The Institute for Cancer Genetics was founded in 1999 as part of a commitment by Columbia University to examine the molecular mechanisms and pathogenesis of cancer. Researchers in the Institute use traditional approaches such as transgenic mice to model human cancers and also take advantage of new technology such as Nextgen sequencing to identify and characterize key proteins and transcriptional and signaling pathways involved in tumor initiation and progression.  Research in the ICG includes cancer genetics and epigenetics, intensive analysis of key protein-protein interactions in oncogenic pathways, DNA damage and repair in normal and neoplastic cells, and experimental anti-cancer therapeutics.